Ryan Deschner
Stock Analyst at Raymond James
(4.80)
# 491
Out of 4,534 analysts
67
Total ratings
70.7%
Success rate
42.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACOG Alpha Cognition | Initiated Coverage: Buy | $20 | $8.34 | +139.81% | 1 | Jul 10, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $10 | $2.93 | +241.30% | 5 | Jul 8, 2026 | |
| ACHV Achieve Life Sciences | Initiated Coverage: Buy | $20 | $6.24 | +220.51% | 1 | Jun 26, 2026 | |
| PRQR ProQR Therapeutics | Maintained: Buy | $14 → $10 | $1.76 | +468.18% | 2 | Jun 26, 2026 | |
| VKTX Viking Therapeutics | Maintained: Buy | n/a | $36.38 | - | 2 | Jun 24, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | n/a | $36.99 | - | 6 | Jun 24, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | n/a | $101.00 | - | 5 | Jun 12, 2026 | |
| ADMA ADMA Biologics | Initiated Coverage: Buy | $21 | $8.75 | +140.00% | 1 | Jun 10, 2026 | |
| LQDA Liquidia | Maintained: Buy | n/a | $77.08 | - | 12 | Jun 4, 2026 | |
| IFRX InflaRx | Maintained: Buy | $9 | $1.82 | +394.51% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $110 → $165 | $116.62 | +41.49% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $23 | $11.50 | +100.00% | 2 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $6.44 | - | 11 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $54 → $143 | $124.15 | +15.18% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $29 → $27 | $16.77 | +61.00% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 → $12 | $5.09 | +135.76% | 4 | Aug 5, 2025 |
Alpha Cognition
Jul 10, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $8.34
Upside: +139.81%
Tvardi Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $10
Current: $2.93
Upside: +241.30%
Achieve Life Sciences
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $6.24
Upside: +220.51%
ProQR Therapeutics
Jun 26, 2026
Maintained: Buy
Price Target: $14 → $10
Current: $1.76
Upside: +468.18%
Viking Therapeutics
Jun 24, 2026
Maintained: Buy
Price Target: n/a
Current: $36.38
Upside: -
Vera Therapeutics
Jun 24, 2026
Maintained: Buy
Price Target: n/a
Current: $36.99
Upside: -
Dianthus Therapeutics
Jun 12, 2026
Maintained: Buy
Price Target: n/a
Current: $101.00
Upside: -
ADMA Biologics
Jun 10, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $8.75
Upside: +140.00%
Liquidia
Jun 4, 2026
Maintained: Buy
Price Target: n/a
Current: $77.08
Upside: -
InflaRx
May 13, 2026
Maintained: Buy
Price Target: $9
Current: $1.82
Upside: +394.51%
May 7, 2026
Maintained: Buy
Price Target: $110 → $165
Current: $116.62
Upside: +41.49%
Mar 13, 2026
Upgraded: Buy
Price Target: $23
Current: $11.50
Upside: +100.00%
Jan 9, 2026
Maintained: Buy
Price Target: n/a
Current: $6.44
Upside: -
Nov 19, 2025
Upgraded: Buy
Price Target: $54 → $143
Current: $124.15
Upside: +15.18%
Aug 8, 2025
Maintained: Buy
Price Target: $29 → $27
Current: $16.77
Upside: +61.00%
Aug 5, 2025
Maintained: Buy
Price Target: $11 → $12
Current: $5.09
Upside: +135.76%